ArticleScience advances2026
PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction.
Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy has revolutionized cancer treatment, yet substantial inter-patient response heterogeneity limits therapeutic benefit to specific patient subsets. Here, we present PathTIGR, a pathway topology-informed graph representation learning framework that systematically integrates biological pathway network topology knowledge with genome variation information for immunotherapy response prediction. PathTIGR uses a three-component design: (i) pathway graph encoder with multihead attention embeding pathway topology knowledge and cancer genomic variants to pathway representation, (ii) transformer module capturing pathway regulatory dependencies, and (iii) multilayer perceptron synthesizing pathway-level representations to predict immunotherapy response. This architecture enables PathTIGR to capture complex molecular interactions underlying immunotherapy response. Comprehensive validation across multiple independent immunotherapy cohorts demonstrates that PathTIGR achieves superior predictive performance compared to established biomarkers and state-of-the-art deep learning approaches while maintaining biological interpretability through identification of key signatures underlying response heterogeneity. PathTIGR represents an interpretable graph-based learning framework that enhances immunotherapy response prediction and elucidates molecular determinants of therapeutic efficacy, thereby facilitating the advancement of precision cancer immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.